O	0	6	Effect	Effect	NN	B-NP
O	7	9	of	of	IN	B-PP
O	10	11	U	U	NN	B-NP
O	11	12	-	-	HYPH	O
O	12	15	995	995	CD	B-NP
O	15	16	,	,	,	O
O	17	18	a	a	DT	B-NP
O	19	25	potent	potent	JJ	I-NP
O	26	31	shark	shark	NN	I-NP
B-Tissue	32	41	cartilage	cartilage	NN	I-NP
O	41	42	-	-	HYPH	B-VP
O	42	49	derived	derive	VBN	B-NP
O	50	62	angiogenesis	angiogenesis	NN	I-NP
O	63	72	inhibitor	inhibitor	NN	I-NP
O	72	73	,	,	,	O
O	74	76	on	on	IN	B-PP
O	77	81	anti	anti	AFX	B-NP
O	81	82	-	-	HYPH	I-NP
O	82	94	angiogenesis	angiogenesis	NN	I-NP
O	95	98	and	and	CC	O
O	99	103	anti	anti	AFX	B-NP
O	103	104	-	-	HYPH	I-NP
B-Cancer	104	109	tumor	tumor	NN	B-NP
O	110	120	activities	activity	NNS	I-NP
O	120	121	.	.	.	O

O	122	132	BACKGROUND	BACKGROUND	NN	B-NP
O	132	133	:	:	:	O
O	134	135	A	A	DT	B-NP
O	136	142	potent	potent	JJ	I-NP
O	143	155	angiogenesis	angiogenesis	NN	I-NP
O	156	165	inhibitor	inhibitor	NN	I-NP
O	165	166	,	,	,	O
O	167	168	U	U	NN	B-NP
O	168	169	-	-	HYPH	O
O	169	172	995	995	CD	B-NP
O	172	173	,	,	,	O
O	174	177	has	have	VBZ	B-VP
O	178	182	been	be	VBN	I-VP
O	183	191	purified	purify	VBN	I-VP
O	192	196	from	from	IN	B-PP
O	197	200	the	the	DT	B-NP
B-Tissue	201	210	cartilage	cartilage	NN	I-NP
O	211	213	of	of	IN	B-PP
O	214	217	the	the	DT	B-NP
O	218	222	blue	blue	JJ	I-NP
O	223	228	shark	shark	NN	I-NP
O	229	230	(	(	(	O
O	230	238	Prionace	Prionace	NN	B-NP
O	239	245	glauca	glauca	NN	I-NP
O	245	246	)	)	)	O
O	246	247	.	.	.	O

O	248	249	U	U	NN	B-NP
O	249	250	-	-	HYPH	O
O	250	253	995	995	CD	B-NP
O	254	256	is	be	VBZ	B-VP
O	257	265	composed	compose	VBN	I-VP
O	266	268	of	of	IN	B-PP
O	269	272	two	two	CD	B-NP
O	273	279	single	single	JJ	I-NP
O	280	288	peptides	peptide	NNS	I-NP
O	289	293	with	with	IN	B-PP
O	294	303	molecular	molecular	JJ	B-NP
O	304	308	mass	mass	NN	I-NP
O	309	311	of	of	IN	B-PP
O	312	314	10	10	CD	B-NP
O	315	318	and	and	CC	I-NP
O	319	321	14	14	CD	I-NP
O	322	325	kDa	kDa	NN	I-NP
O	325	326	,	,	,	O
O	327	339	respectively	respectively	RB	B-ADVP
O	339	340	.	.	.	O

O	341	350	MATERIALS	MATERIALS	NNS	B-NP
O	351	354	AND	AND	CC	I-NP
O	355	362	METHODS	METHODS	NNS	I-NP
O	362	363	:	:	:	O
O	364	365	U	U	NN	B-NP
O	365	366	-	-	HYPH	O
O	366	369	995	995	CD	B-NP
O	370	373	was	be	VBD	B-VP
O	374	382	designed	design	VBN	I-VP
O	383	385	to	to	TO	B-VP
O	386	391	study	study	VB	I-VP
B-Cell	392	397	human	human	JJ	B-NP
I-Cell	398	407	umbilical	umbilical	JJ	I-NP
I-Cell	408	412	vein	vein	NN	I-NP
I-Cell	413	424	endothelial	endothelial	JJ	I-NP
I-Cell	425	429	cell	cell	NN	I-NP
O	430	431	(	(	(	O
B-Cell	431	436	HUVEC	HUVEC	NN	B-NP
O	436	437	)	)	)	O
O	438	447	migration	migration	NN	B-NP
O	448	451	and	and	CC	I-NP
O	452	465	proliferation	proliferation	NN	I-NP
O	466	468	in	in	FW	B-ADVP
O	469	474	vitro	vitro	FW	I-ADVP
O	475	478	and	and	CC	O
O	479	491	angiogenesis	angiogenesis	NN	B-NP
O	492	499	induced	induce	VBN	B-VP
O	500	502	by	by	IN	B-PP
O	503	506	TNF	TNF	NN	B-NP
O	507	512	alpha	alpha	NN	I-NP
O	513	515	in	in	IN	B-PP
O	516	523	chicken	chicken	NN	B-NP
B-Multi-tissue_structure	524	539	chorioallantoic	chorioallantoic	JJ	I-NP
I-Multi-tissue_structure	540	548	membrane	membrane	NN	I-NP
O	549	550	(	(	(	O
B-Multi-tissue_structure	550	553	CAM	CAM	NN	B-NP
O	553	554	)	)	)	O
O	554	555	.	.	.	O

O	556	567	Furthermore	Furthermore	RB	B-ADVP
O	567	568	,	,	,	O
O	569	571	we	we	PRP	B-NP
O	572	582	determined	determine	VBD	B-VP
O	583	586	the	the	DT	B-NP
O	587	594	ability	ability	NN	I-NP
O	595	597	of	of	IN	B-PP
O	598	599	U	U	NN	B-NP
O	599	600	-	-	HYPH	O
O	600	603	995	995	CD	B-NP
O	604	606	to	to	TO	B-PP
O	607	617	inhibiting	inhibit	VBG	B-VP
B-Cell	618	623	tumor	tumor	NN	B-NP
I-Cell	624	628	cell	cell	NN	I-NP
O	629	635	growth	growth	NN	I-NP
O	636	639	and	and	CC	O
O	640	650	metastasis	metastasis	NN	B-NP
O	650	651	.	.	.	O

O	652	659	RESULTS	RESULTS	NNS	B-NP
O	659	660	:	:	:	O
O	661	662	U	U	NN	B-NP
O	662	663	-	-	HYPH	O
O	663	666	995	995	CD	B-NP
O	667	668	(	(	(	O
O	668	670	15	15	CD	B-NP
O	671	674	and	and	CC	I-NP
O	675	677	30	30	CD	I-NP
O	678	688	micrograms	microgram	NNS	I-NP
O	688	689	/	/	SYM	B-NP
O	689	691	ml	ml	NN	I-NP
O	691	692	)	)	)	O
O	693	701	markedly	markedly	RB	B-ADVP
O	702	711	inhibited	inhibit	VBD	B-VP
B-Cell	712	717	HUVEC	HUVEC	NN	B-NP
O	718	727	migration	migration	NN	I-NP
O	728	731	and	and	CC	O
O	731	732	,	,	,	O
O	733	735	at	at	IN	B-PP
O	736	738	15	15	CD	B-NP
O	738	739	-	-	HYPH	I-NP
O	739	741	50	50	CD	I-NP
O	742	752	micrograms	microgram	NNS	I-NP
O	752	753	/	/	SYM	B-NP
O	753	755	ml	ml	NN	I-NP
O	756	764	produced	produce	VBD	B-VP
O	765	766	a	a	DT	B-NP
O	767	771	dose	dose	NN	I-NP
O	771	772	-	-	HYPH	B-NP
O	772	781	dependent	dependent	JJ	I-NP
O	782	789	decline	decline	NN	I-NP
O	790	792	in	in	IN	B-PP
O	793	794	[	[	(	O
O	794	796	3H	3H	NN	B-NP
O	796	797	]	]	)	O
O	797	798	-	-	HYPH	B-NP
O	798	807	thymidine	thymidine	NN	I-NP
O	808	821	incorporation	incorporation	NN	I-NP
O	821	822	.	.	.	O

O	823	825	30	30	CD	B-NP
O	826	829	and	and	CC	I-NP
O	830	832	50	50	CD	I-NP
O	833	843	micrograms	microgram	NNS	I-NP
O	843	844	/	/	SYM	B-NP
O	844	846	ml	ml	NN	I-NP
O	847	849	of	of	IN	B-PP
O	850	851	U	U	NN	B-NP
O	851	852	-	-	HYPH	B-NP
O	852	855	995	995	CD	I-NP
O	855	856	,	,	,	O
O	857	861	when	when	WRB	B-ADVP
O	862	867	added	add	VBN	B-VP
O	868	870	to	to	TO	B-PP
O	871	874	TNF	TNF	NN	B-NP
O	875	880	alpha	alpha	SYM	B-NP
O	880	881	-	-	HYPH	B-VP
O	881	888	induced	induce	VBN	B-NP
O	889	901	angiogenesis	angiogenesis	NN	I-NP
O	902	908	caused	cause	VBD	B-VP
O	909	922	discontinuous	discontinuous	JJ	B-NP
O	923	926	and	and	CC	I-NP
O	927	936	disrupted	disrupt	VBN	I-NP
B-Multi-tissue_structure	937	942	blood	blood	NN	I-NP
I-Multi-tissue_structure	943	950	vessels	vessel	NNS	I-NP
O	950	951	.	.	.	O

O	952	960	Moreover	Moreover	RB	B-ADVP
O	960	961	,	,	,	O
O	962	963	U	U	NN	B-NP
O	963	964	-	-	HYPH	O
O	964	967	995	995	CD	B-NP
O	968	969	(	(	(	O
O	969	971	30	30	CD	B-NP
O	972	982	micrograms	microgram	NNS	I-NP
O	982	983	/	/	SYM	B-NP
O	983	985	ml	ml	NN	I-NP
O	985	986	)	)	)	O
O	987	995	markedly	markedly	RB	B-ADVP
O	996	1005	prevented	prevent	VBD	B-VP
O	1006	1017	collagenase	collagenase	NN	B-NP
O	1017	1018	-	-	HYPH	B-NP
O	1018	1025	induced	induce	VBN	I-NP
O	1026	1040	collagenolysis	collagenolysis	NN	I-NP
O	1040	1041	.	.	.	O

O	1042	1044	In	In	IN	B-PP
O	1045	1053	addition	addition	NN	B-NP
O	1053	1054	,	,	,	O
O	1055	1059	when	when	WRB	B-ADVP
O	1060	1063	200	200	CD	B-NP
O	1064	1074	micrograms	microgram	NNS	I-NP
O	1075	1076	U	U	NN	I-NP
O	1076	1077	-	-	HYPH	B-NP
O	1077	1080	995	995	CD	I-NP
O	1081	1084	was	be	VBD	B-VP
O	1085	1093	injected	inject	VBN	I-VP
O	1094	1095	i	i	NN	B-NP
O	1095	1096	.	.	.	I-NP
O	1096	1097	p	p	NN	I-NP
O	1097	1098	.	.	.	O
O	1099	1103	into	into	IN	B-PP
O	1104	1108	mice	mouse	NNS	B-NP
O	1109	1111	it	it	PRP	B-NP
O	1112	1122	suppressed	suppress	VBD	B-VP
B-Cell	1123	1130	sarcoma	sarcoma	NN	B-NP
I-Cell	1130	1131	-	-	HYPH	B-NP
I-Cell	1131	1134	180	180	CD	I-NP
I-Cell	1135	1139	cell	cell	NN	I-NP
O	1140	1146	growth	growth	NN	I-NP
O	1147	1150	and	and	CC	I-NP
B-Cell	1151	1154	B16	B16	NN	I-NP
I-Cell	1154	1155	-	-	HYPH	B-NP
I-Cell	1155	1158	F10	F10	NN	I-NP
I-Cell	1159	1164	mouse	mouse	NN	I-NP
I-Cell	1165	1173	melanoma	melanoma	NN	I-NP
I-Cell	1174	1178	cell	cell	NN	I-NP
O	1179	1189	metastasis	metastasis	NN	I-NP
O	1190	1192	in	in	FW	B-ADVP
O	1193	1197	vivo	vivo	FW	I-ADVP
O	1197	1198	.	.	.	O

O	1199	1210	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1210	1211	:	:	:	O
O	1212	1217	These	These	DT	B-NP
O	1218	1225	results	result	NNS	I-NP
O	1226	1233	suggest	suggest	VBP	B-VP
O	1234	1238	that	that	IN	B-SBAR
O	1239	1242	the	the	DT	B-NP
O	1243	1247	anti	anti	AFX	I-NP
O	1247	1248	-	-	HYPH	I-NP
O	1248	1258	angiogenic	angiogenic	JJ	I-NP
O	1259	1266	effects	effect	NNS	I-NP
O	1267	1269	of	of	IN	B-PP
O	1270	1271	U	U	NN	B-NP
O	1271	1272	-	-	HYPH	O
O	1272	1275	995	995	CD	B-NP
O	1276	1279	may	may	MD	B-VP
O	1280	1282	be	be	VB	I-VP
O	1283	1285	be	be	VB	I-VP
O	1286	1289	due	due	JJ	B-ADJP
O	1290	1292	to	to	TO	B-PP
O	1293	1305	interference	interference	NN	B-NP
O	1306	1310	with	with	IN	B-PP
O	1311	1314	the	the	DT	B-NP
O	1315	1328	proliferation	proliferation	NN	I-NP
O	1329	1332	and	and	CC	I-NP
O	1333	1342	migration	migration	NN	I-NP
O	1343	1345	of	of	IN	B-PP
B-Cell	1346	1352	HUVECs	HUVEC	NNS	B-NP
O	1353	1355	as	as	RB	B-CONJP
O	1356	1360	well	well	RB	I-CONJP
O	1361	1363	as	as	IN	I-CONJP
O	1364	1374	inhibition	inhibition	NN	B-NP
O	1375	1377	of	of	IN	B-PP
O	1378	1392	collagenolysis	collagenolysis	NN	B-NP
O	1392	1393	,	,	,	O
O	1394	1401	thereby	thereby	RB	B-VP
O	1402	1409	leading	lead	VBG	I-VP
O	1410	1412	to	to	TO	B-PP
O	1413	1423	inhibition	inhibition	NN	B-NP
O	1424	1426	of	of	IN	B-PP
O	1427	1431	both	both	CC	O
O	1432	1444	angiogenesis	angiogenesis	NN	B-NP
O	1445	1448	and	and	CC	O
B-Cell	1449	1454	tumor	tumor	NN	B-NP
I-Cell	1455	1459	cell	cell	NN	I-NP
O	1460	1466	growth	growth	NN	I-NP
O	1466	1467	.	.	.	O

